CLEC4E as a New Tumor Marker for Early Diagnosis of GIT Tumors

Abstract

During the period from the beginning of December 2018 to the end of May 2019, 108 resident of Babylon were included to participate in the current study, were divided into two main groups: 81 patients with GIT diseases, their age ranged from 12-80 years; and the controls group (27 individuals) with the age 17-71 years old. Furthermore, the patient group was divided into two subgroups, the first involved 51 patients with GIT tumors and the other with non-tumoral diseases of GIT (30 individuals suffered non tumoral GIT illness were enrolled as a pathological control group). CLEC4L, Serotonin were evaluated in the sera samples of the study groups. The current study revealed statistical significant increase in the levels of serotonin while it showed significant decrease in the levels of CLEC4L in the sera testers of patients with malignant GIT tumors when compared to benign GIT tumors, pathological GIT control, and healthy control groups. The present study showed that the relationship between CLEC4E with serotonin became negative. Serotonin showed the (88%) sensitivity among the assessed criteria followed by CLEC4L (76%).